Prologue Medicines
Michael Askenase is a highly experienced scientist specializing in AI and computational science, currently serving as Senior Scientist II at Prologue Medicines since December 2021. As an early team member, Michael initiated the development of Prologue's DELVE platform and leads the computational team focused on target discovery. Prior to this role, Michael held various positions at Yale University School of Medicine from November 2015 to December 2021, engaging in research on intracerebral hemorrhage and inflammatory pathology. Michael also completed a Pre-Doctoral Research Fellowship at the National Institutes of Health, where research focused on hematopoiesis during infection. Early career experiences included research technician roles at Tufts University School of Medicine and an undergraduate research position at Biogen Idec. Michael earned a Ph.D. in Immunology from the University of Pennsylvania and a B.S. in Biology from Tufts University.
This person is not in any teams
This person is not in any offices
Prologue Medicines
1 followers
Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.